Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles

被引：6
|
作者：
Lin, Hung-Yao [1 ]
Tseng, Tai-Chung [1 ,2 ,3 ]
机构：
[1] Natl Taiwan Univ Hosp, Div Gastroenterol & Hepatol, Dept Internal Med, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Med Res, 1 Chang Te St, Taipei 10002, Taiwan
来源：
CLINICAL AND MOLECULAR HEPATOLOGY | 2022年 / 28卷 / 02期
关键词：
Tenofovir disoproxil fumarate; Tenofovir alafenamide; Hyperlipidemias; Tenofovir;
D O I：
10.3350/cmh.2022.0028
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：181 / 182
页数：2
相关论文
共 50 条
  • [1] Tenofovir Alafenamide: A Review in Chronic Hepatitis B
    Lesley J. Scott
    Henry L. Y. Chan
    Drugs, 2017, 77 : 1017 - 1028
  • [2] Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis
    Eui Gwon Hwang
    Eun-Ae Jung
    Jeong-Ju Yoo
    Sang Gyune Kim
    Young Seok Kim
    Hepatology International, 2023, 17 : 860 - 869
  • [3] Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis
    Hwang, Eui Gwon
    Jung, Eun-Ae
    Yoo, Jeong-Ju
    Kim, Sang Gyune
    Kim, Young Seok
    HEPATOLOGY INTERNATIONAL, 2023, 17 (04) : 860 - 869
  • [4] Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection
    Basit, Syed Abdul
    Dawood, Altaf
    Ryan, John
    Gish, Robert
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (07) : 707 - 716
  • [5] Tenofovir Alafenamide for the Treatment of Chronic Hepatitis B Monoinfection
    Childs-Kean, Lindsey M.
    Egelund, Eric F.
    Jourjy, Jacqueline
    PHARMACOTHERAPY, 2018, 38 (10): : 1051 - 1057
  • [6] Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
    Hong, Hyeyeon
    Choi, Won-Mook
    Lee, Danbi
    Shim, Ju Hyun
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    Choi, Jonggi
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (01) : 49 - 63
  • [7] Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B
    Liu, Rui
    Qiao, Jin
    Zhang, Lin
    Dou, Zhihua
    MEDICINE, 2024, 103 (20) : E37953
  • [8] The Cost-Effectiveness of Tenofovir Alafenamide for Chronic Hepatitis B Virus in Taiwan
    Tan, Elise Chia-Hui
    Yehoshua, Alon
    Jeyakumar, Sushanth
    Peng, Pongo
    Lin, Amy
    Smith, Nathaniel J.
    Kachru, Nandita
    MDM POLICY & PRACTICE, 2025, 10 (01)
  • [9] Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy
    Ogawa, Eiichi
    Furusyo, Norihiro
    Nguyen, Mindie H.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 3197 - 3204
  • [10] Investigation of Efficacy and Safety in Chronic Hepatitis B Patients Receiving Tenofovir Alafenamide Treatment
    Kahveci, Huseyin Nadir
    Yildiz, Orhan
    Karabulut, Kaan
    Ture, Zeynep
    Unuvar, Gamze Kalin
    Aygen, Bilgehan
    JOURNAL OF CLINICAL PRACTICE AND RESEARCH, 2024, 46 (04):
12345